HC Wainwright Has Lowered Expectations for Evolus (NASDAQ:EOLS) Stock Price

Evolus (NASDAQ:EOLS) had its price target lowered by equities researchers at HC Wainwright from $20.00 to $13.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 183.22% from the stock’s previous close. HC Wainwright also issued estimates for Evolus’ Q4 2025 earnings at $0.01 EPS.

Several other equities analysts have also issued reports on the company. Needham & Company LLC restated a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Mizuho cut their target price on Evolus from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Monday, December 1st. Stifel Nicolaus reduced their target price on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. Wall Street Zen upgraded shares of Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, BTIG Research dropped their price objective on shares of Evolus from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $17.50.

Evolus Price Performance

Shares of Evolus stock opened at $4.59 on Tuesday. Evolus has a fifty-two week low of $4.48 and a fifty-two week high of $17.12. The firm has a fifty day moving average price of $6.11 and a two-hundred day moving average price of $6.75. The company has a market cap of $297.52 million, a PE ratio of -4.99 and a beta of 1.11.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. The company had revenue of $68.97 million for the quarter, compared to the consensus estimate of $91.23 million. Analysts expect that Evolus will post -0.61 earnings per share for the current fiscal year.

Insider Activity at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the business’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the sale, the insider owned 354,388 shares in the company, valued at approximately $2,533,874.20. The trade was a 2.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Evolus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Evolus by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after buying an additional 1,838 shares in the last quarter. Millennium Management LLC increased its holdings in Evolus by 1.7% during the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock valued at $16,746,000 after purchasing an additional 23,605 shares in the last quarter. Jones Financial Companies Lllp acquired a new stake in Evolus during the 1st quarter valued at $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Evolus by 36.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company’s stock valued at $1,883,000 after purchasing an additional 41,513 shares during the last quarter. Finally, Jane Street Group LLC boosted its stake in Evolus by 484.8% in the first quarter. Jane Street Group LLC now owns 69,947 shares of the company’s stock worth $841,000 after purchasing an additional 57,987 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.